Leucovorin
Leucovorin (leucovorin) is a small molecule pharmaceutical. Leucovorin was first approved as Leucovorin calcium on 1982-01-01. It is used to treat folic acid deficiency and megaloblastic anemia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Leucovorin (discontinued: Leucovorin, Wellcovorin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enbrace hr | unapproved drug other | 2025-01-02 |
| enlyte | unapproved drug other | 2022-07-01 |
| leucovorin | ANDA | 2014-09-26 |
| leucovorin calcium | ANDA | 2025-01-07 |
| paxlyte | unapproved drug other | 2024-12-19 |
| pyrimethamine leucovorin | unapproved drug other | 2015-11-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| folic acid deficiency | EFO_0001070 | D005494 | E53.8 |
| megaloblastic anemia | HP_0001889 | D000749 | D53.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
No data
Drug
General
| Drug common name | Leucovorin |
| INN | calcium folinate |
| Description | Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O |
Identifiers
| PDB | — |
| CAS-ID | 58-05-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1679 |
| ChEBI ID | 15640 |
| PubChem CID | 6006 |
| DrugBank | DB03256 |
| UNII ID | RPR1R4C0P4 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Leucovorin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
Black-box warning for: Enlyte
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use